NCT06710405 The Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Pain and Recovery in Children (< 7 Years Old) Undergoing Thoracoscopic Surgery
| NCT ID | NCT06710405 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Seoul National University Hospital |
| Condition | Pain Management After Surgery |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2024-12-09 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2024-12-09 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the efficacy of intraoperative intravenous lidocaine infusion on postoperative pain management and recovery in pediatric patients undergoing thoracoscopic pulmonary resection.
Eligibility Criteria
Inclusion Criteria: * Pediatric patients aged under 7 years undergoing thoracoscopic pulmonary resection Exclusion Criteria: * cardiac dysfunction requiring vasopressors or inotropic agents * atrioventricular block or bradycardia * Liver or kidney dysfunction * Hypersensitivity to local anesthetics
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06710405 clinical trial?
This trial is open to participants of all sexes, aged 6 Months or older, up to 7 Years, studying Pain Management After Surgery. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06710405 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT06710405 currently recruiting?
Yes, NCT06710405 is actively recruiting participants. Contact the research team at muslab6@snu.ac.kr for enrollment information.
Where is the NCT06710405 trial being conducted?
This trial is being conducted at Seoul, South Korea.
Who is sponsoring the NCT06710405 clinical trial?
NCT06710405 is sponsored by Seoul National University Hospital. The trial plans to enroll 80 participants.